MacroGenics (MGNX) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MacroGenics (MGNX) has outperformed Zentalis Pharmaceuticals (ZNTL) over the past year, gaining 113.7% versus a gain of 45.9%. Over five years, MGNX leads with a -81.1% price change compared with -96.5% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $238.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | ZNTL |
|---|---|---|
| Share price | $3.74 | $2.64 |
| Market cap | $238.24M | $259.04M |
| 1-day change | +5.35% | +5.18% |
| YTD return | +132.30% | +95.56% |
| 1-year return | +113.71% | +45.86% |
| 5-year return | -81.05% | -96.48% |
| EPS (TTM) | $-1.80 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $6.95 |
| 52-week low | $1.29 | $1.21 |
| Distance from 52-week high | -26.38% | -62.01% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +113.90% | +177.65% |
| Average volume | 622.92K | 1.21M |
| Shares outstanding | 63.70M | 98.12M |
| Employees | 293 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed ZNTL by 67.9 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
MGNX vs ZNTL FAQ
Which is bigger, MacroGenics or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $238.24M for MacroGenics (MGNX).
Which stock has performed better over the past year, MGNX or ZNTL?
MGNX returned +113.71% over the past 12 months, compared with +45.86% for ZNTL (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.